Bleomycin induced flagellate pigmentation and sclerodermoid change co-existent in a patient of Hodgkin’s lymphoma

Authors

  • Sudip Das
  • Joyeeta Chowdhury
  • Suchibrata Das

DOI:

https://doi.org/10.66344/jpad.23.4.2013.324

Keywords:

Bleomycin, flagellate pigmentation, sclerodermoid change

Abstract

Bleomycin is a chemotherapeutic drug known to cause a variety of cutaneous side-effects. Pigmentary changes are the commonest. We report a case of bleomycin induced flagellate pigmentation and sclerodermoid change co-existent in a patient of Hodgkin’s lymphoma. 

References

Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin N Am. 1986;70:187-209.

Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Int Med. 1981;94:66-74.

Soble AR. Chronic bleomycin-associated Raynaud's phenomenon. Cancer Treatment Reports. 1978;60:570.

Gupta L, Tanwar R K, Khare A, Jain S. Bleomycin induced flagellate pigmentation. Indian J Dermatol Venereol Leprol. 2002;68:158-9.

Duhra P, Ilchyshyn A, Das RN. Bleomycin-induced flagellate erythema. Clin Exp Dermatol. 1991;16:216-7.

Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin. J Rheumatol. 1992;19:294-6.

Mowad CM, Nguyen TV, Elenitsas R, Leyden JJ. Bleomycin induced flagellate dermatitis: a clinical and histopathological review. Br J Dermatol. 1994;131:700-2.

Cortina P, Garrido JA, Tomas JF et al. 'Flagellate' erythema from bleomycin with histopathological findings suggestive of inflammatory oncotaxis. Dermatologica. 1990;180:106-9.

Downloads

Published

2016-12-16

How to Cite

1.
Das S, Chowdhury J, Das S. Bleomycin induced flagellate pigmentation and sclerodermoid change co-existent in a patient of Hodgkin’s lymphoma. J Pak Assoc Dermatol [Internet]. 2016Dec.16 [cited 2026Apr.12];23(4):440-2. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/324

Issue

Vol. 23 No. 4 (2013): October - December

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.